Selecting projects to fund

So far, all available Parkinson treatments are symptom treating: they help to (temporarily) hide the symptoms of the disease. In order to get to true breakthroughs, the Demoucelle Parkinson Charity support those projects that are disease modifying, projects that slow down or halt the progression of the disease, or even help to reverse the disease.

When selecting projects that can benefit from funding from the Demoucelle Parkinson Charity, Patrick and Anne-Marie favor European projects that are in or close to the stage of clinical trials (where treatments are tested on humans).

So far, the Demoucelle Parkinson Charity has invested in 9 promising projects.

Steering funded projects

We support exciting and promising disease-modifying projects in Europe in collaboration with the Michael J. Fox Foundation.

*** 16/06/2022 ***

  • InterMed
    (DPC invested in 2012).
    Objective: identify the potential of a molecule to be neuroprotective and become a disease-modifying therapeutic. Read more 

  • Affiris: The Affitope Parkinson Vaccine
    (DPC invested in 2012)
    Objective: perform first phase clinical trial and check impact of the vaccine on α-synuclein, a brain component that plays a central role in the pathogenesis of Parkinson's Disease. Watch our video Read more
    • Exenatide 
      (DPC invested in 2013)
      Objective: perform a randomized, double-blind, placebo-controlled, proof-of-concept trial to confirm whether the preliminary findings of beneficial effects seen in both motor and non-motor PD symptoms can be replicated. Read more
    • nLife Thera 
      (DPC invested in 2015)
      Objective: characterize the dose and efficacy of a new molecule in a model of Parkinson's disease vs a healthy model. Watch our video  Read more.
      • AC Immune
        (DPC invested in 2015 & 2018)
        Objective: develop a brain imaging agent for alpha-synuclein, a key protein involved in PD pathology. Watch our video  Read more
      • Khondrion
        (DPC invested in 2016)
        Objective: test the effectiveness of a molecule against the mitochondrial dysfunction, often noted in Parkinson’s Disease. Read more
      • Nilotinib
        (DPC invested in 2016 & 2017)
        Objective: check whether the effectiveness of the medicine, shown in open trials, is confirmed in a large double-blind, placebo-controlled trial. Read more. Further info.
      • ADx Neurosciences
        (DPC invested in 2017)
        Objective: develop guidelines for clinical trials.
      • ATP10B
        (DPC invested in 2019)
        Objective: better understand the mutation of this gene, and its potential impact on Parkinson’s disease. Read more
      • ATP13A2
        (DPC invested in 2020)
        Objective: To develop a pre-clinical drug candidate   Read more 

      • University of Texas
        (DPC invested in 2021)
        Objective: To carry out human trials to test whether multiple intravenous infusions of mesenchymal stem cells will significantly slow the progression of Parkinson’s disease. Read more 

      • Modag Anle 138b
        (DPC invested in 2022)
        Objective: Further in-patient testing of a drug targeting the buildup of protein alpha-synuclein in the brain. Read more

      The Demoucelle Parkinson Charity receives frequent project updates and participates in project check-in calls and in-person project assessments organized by staff of the Michael J. Fox Foundation.

      Please click here to read updates on 9 of our 12 projects (25/11/2021). 


      You want more info? Send us een email (info@demoucelle) and we'll get back to you